Omicron cases in US could peak by end of January, Fauci says
Pfizer / BioNTech’s mRNA vaccine is 92% effective in preventing Covid-19 in young people aged 12 to 17, according to data released Thursday in the Centers for Disease Control’s Weekly Morbidity and Mortality Report. Prevention in the United States.
Researchers examined 243 adolescents without a positive Covid-19 test in Arizona between July 25 and December 4. The teens or their parents took nasal swabs and sent them in for weekly PCR tests. Twenty-one teenagers tested positive during the study period, and 18 of them reported symptoms. The results are consistent with clinical trials and other studies, the researchers report.
The study took place at a time when Delta was the dominant circulating variant of the coronavirus. Initial results suggest that the latest variant, Omicron, may be less sensitive to vaccines. A booster dose increases levels of protection, but the boosters have not been approved for children and adolescents in the United States.
The United States Food and Drug Administration has approved the Pfizer / BioNTech vaccine for people as young as 16 years old, and it is available under emergency use authorization for ages 5 to 15.
Further research published in the MMWR on Thursday found that reports of serious adverse events were rare in children aged 5 to 11 who received the vaccine.
The study examined reports from two safety monitoring systems, the Vaccine Adverse Event Reporting System (VAERS) and v-safe, from November 3 to December 19. During this period, approximately 8.7 million doses of Pfizer / BioNTech vaccine were administered. for children aged 5 to 11.
VAERS received 4,249 reports of adverse events, and over 97% were not serious. About 100 serious events have been reported, most often fever, vomiting and increased levels of troponin, a protein found in heart muscle. There were 12 reports of seizures and 15 reports of myocarditis, of which 11 were verified.
Learn more about the study: V-safe recruited 42,504 vaccinated children aged 5 to 11. After the first dose of the vaccine, 54.8% reported local reactions and 34.7% reported systemic reactions; after the second dose, 57.5% reported local reactions and 40.9% reported systemic reactions. The most frequently reported reactions were injection site pain, fatigue and headache.
The researchers noted that their results are consistent with clinical trials and that VAERS and v-safe are based on reports that may be biased or underreported. “Parents and guardians of children aged 5 to 11 should be informed that local and systemic reactions are expected after vaccination,” they wrote. “Vaccination remains the most effective way to prevent infection with Covid-19. “